Streetbeat News

Stock Prices

BIOE

CATX

EXFY

Insiders are buying shares of Expensify, Bio Essence, and Perspective Therapeutics, indicating confidence in these companies despite recent challenges. Expensify posted downbeat quarterly results, Bio Essence's stock surged 127% in the past month, and Perspective Therapeutics announced an $80 million underwritten offering.

Portfolio Pulse from Avi Kapoor

June 04, 2024 | 11:24 am

O

Realty Income has revised its 2024 outlook, adjusting its normalized FFO per share to a range of $4.19 - $4.28 and AFFO per share to $4.15 - $4.21. The company also increased its expected 2024 investment volume to approximately $3.0 billion from the previous guidance of $2.0 billion.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 11:13 am

VKTX

Viking Therapeutics released 52-week histologic data from its Phase 2B VOYAGE study of VK2809 in non-alcoholic steatohepatitis (NASH). The results showed significant improvements in NASH resolution and fibrosis among VK2809-treated patients compared to placebo, with similar adverse events.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 11:11 am

GLYC

GlycoMimetics shares are trading higher following the announcement of positive results from its Phase 3 study of uproleselan in R/R AML, showing a significant improvement in median overall survival.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 11:09 am

LAD

Lithia & Driveway (LAD) has announced a $350 million increase to its share repurchase authorization, bringing the total funds available for future repurchases to $660 million.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 11:05 am

BBWI

Bath & Body Works (BBWI) projects Q2 net sales to be between -2% and 0%, with adjusted EPS expected to be between $0.31 and $0.36, compared to the estimated $0.39.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 11:05 am

RMBL

RumbleOn has appointed Tiffany Kice as its new CFO, effective June 24, 2024. Kice joins from Pegasus Logistics Group, where she served as CFO since 2020.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 11:03 am

ANNX

Annexon announced that its drug ANX005 at 75 mg/kg outperformed placebo on multiple endpoints in a clinical trial, but did not achieve statistical significance on the primary endpoint of GBS-DS at week 8.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 11:03 am

BBWI

Bath & Body Works has announced its FY24 adjusted EPS guidance to be in the range of $3.05 to $3.35, compared to the analyst estimate of $3.31.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 11:03 am

NNVC

NanoViricides reported that its lead antiviral agent NV-387 showed a desirable blood concentration profile in a non-human primate model, maintaining a stable concentration over 24 hours with a dose-dependent increase.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 11:03 am